MSCs were used in several pilot studies for treatment of severe COVID-19, demonstrating their efficiency by patient clinical improvement, better oxygenation and decreased inflammatory markers (CRP, IL-6, TNF-α, procalcitonin) with no observed adverse effects [204,219,220,221,222]. This evidence concerns the gene IL6 and COVID-19.